State Street Health Care Select Sector SPDR ETF · ARCA (us_market)
— · — · —
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2020-01-22$104.73 RISE2020-03-23$74.62 PEAK2020-06-08$103.92 138d | -28.8% 61d | Missed | Missed | — | — | +39.3% 77d | Missed |
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
Wall Street closed higher on Thursday, driven by tech and healthcare stocks.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad
As UnitedHealth Group has considerably outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.04% and the actively t
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7%, and the actively tra
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the
West Pharmaceutical Services has considerably outperformed the broader market over the past 52 weeks, and Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Waters Corporation has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Wall Street closed higher on Friday, driven by defensive stocks and falling bond yields.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7% and the actively trad
Charles River Laboratories has underperformed the S&P 500 over the past 52 weeks, yet Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.
While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Labcorp Holdings has lagged behind the broader market over the past year, yet analysts remain highly optimistic about the stock’s prospects.
Quest Diagnostics is keeping analysts reasonably upbeat as steady execution and momentum continue supporting Wall Street confidence.
ResMed continues to command steady Wall Street confidence despite recent stock pressure and a few bumps along the road.